What smart money is saying about Merus
MRUS
No fund has written a full thesis on Merus in our archive, but 1 fund letter reports a position in it, most recently Timessquare US Small Cap Growth Strategy in September 2025.
Get an email when a fund buys, sells or pitches it
1
Reported positions
0
Bought
0
Sold
1
Letter
Position history
Every position in Merus on record in the archive was reported in Q3 2025, across 1 fund letter, with no move described.
| Quarter | Letters | Bought | Sold | Theses |
|---|---|---|---|---|
| Q3 2025 | 1 | 0 | 0 | 0 |
Bought and Sold count moves: the same sentence published by several funds of one house in a quarter counts once.
Fund activity · 1 position
- September 2025
“Climbing by 79% was Merus, a biopharma developer of immune-oncology treatments for certain tumors.”
Merus
Read the letters behind these Merus positions
Every quote above comes from a fund letter in our archive. Get unlimited access to the letters themselves, and to Warren AI, which reads all of them for you.
View plans→Share this ledger